HTG Molecular Diagnostics, Inc. — Cyborg Score 3/10

Strategic Profile

The company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. It distributes its instruments and consumables directly in the United States and Europe, serving biopharmaceutical companies, academic research centers, and molecular testing laboratories.

Cyborg Score Rationale

The company filed for Chapter 11 bankruptcy, though it plans to operate while working out a plan to pay its debts. Despite having a differentiated platform technology, the company faces significant financial distress. Market opportunity in precision medicine remains substantial, but execution challenges are evident.

Top Insights

• HTG Edge platform enables analysis of 2,500+ genes from minimal samples (single micron tissue sections or 12.5 microliter liquid biopsy)
• Company established in 1997, providing 29 years of molecular profiling expertise and technology development
• Trailing twelve-month revenue approximately $6.21M indicates revenue generation despite financial challenges
• Market opportunity strong: miRNA sequencing and assays market projected to grow from $379M (2024) to $763.1M (2030) at 12.4% CAGR, driven by rising cancer prevalence and NGS advancements

Named Competitors

• NextSeq — Leading next-generation sequencing platform
• QIAseq — Sample-to-insight sequencing solutions
• Bio-Techne — Life sciences tools and reagents

Recent Developments

• Chapter 11 bankruptcy filing (timing not specified in available sources)
• (May 2023) Reported achievement of technical milestone in drug discovery business

Open the full interactive HTG Molecular Diagnostics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.